Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of sitagliptin + metformin fixed-dose combination vs pioglitazone in type 2 diabetes mellitus
2007-002218-21Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing MK-0431A fixed-dose combination (sitagliptin + metformin) with Pioglitazone 45 mg once daily (2 arms). Primary endpoints: Change in HbA1c at Week 40 and Proportion achieving glycemic goal at Week 40. Started Oct 2007; status: completed.
02
Drugs
sitagliptinmetforminpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-002218-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002218-21.